Osteoarthritis Injectables Market Size, Share & Trends Analysis Report By Injection Type (Hyaluronic Acid Injections, Corticosteroids Injections), By Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), By End-use, And Segment Forecasts, 2024 - 2030

Osteoarthritis Injectables Market Size, Share & Trends Analysis Report By Injection Type (Hyaluronic Acid Injections, Corticosteroids Injections), By Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), By End-use, And Segment Forecasts, 2024 - 2030


Osteoarthritis Injectables Market Growth & Trends

The global osteoarthritis injectables market size is anticipated to reach USD 11.42 billion by 2030, exhibiting a CAGR of 6.82% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing growth, influenced by several key factors. Women aged 50 to 60 are more susceptible to developing hand and knee osteoarthritis (OA) compared to men, due to hormonal changes and musculoskeletal differences, as highlighted by Arthritis-health data from January 2021. Additionally, obesity rates, higher among women according to the National Institutes of Health, further increase the risk. In the U.S. alone, it is projected that the number of osteoarthritis patients will reach 70 million by 2040.

The growing geriatric population is a significant driver for market expansion. An NCBI report from May 2023 predicts that the combination of an aging population and obesity will more than double the number of osteoarthritis patients to 67 million by 2030. The majority of cases are expected to occur in individuals aged 65 and above, with 45% of current osteoarthritis patients falling into this age group, according to an OAAA study supported by the CDC in March 2024. This demographic shift impacts productivity, reducing work efficiency and increasing the disease burden.

Research and development activities are also boosting the osteoarthritis injectables market growth, with pharmaceutical companies and research institutes focusing on the development of novel drugs for OA management. BioSenic's announcement in January 2024 regarding the phase 3 study of JTA-004, an innovative treatment for knee OA, demonstrates the industry's commitment to advancing treatment options. Academic and research institutes are also actively involved in developing novel therapies. For instance, a GP130 investigational drug, reported in March 2023, shows promise in managing inflammation and pain. Additionally, Kolon TissueGene, Inc.'s Phase 2 clinical trial for TG-C in hip OA aims to evaluate pain and quality-of-life improvements.

The adoption of oral drugs, surgery, and home remedies such as gin-soaked raisins or wearing copper bracelets for the treatment of OA is expected to adversely affect market growth. The adoption of oral and topical treatment drugs such as analgesics, NSAIDs, and corticosteroids, is increasing due to the patient-centric approach and ease of use. Moreover, increase in research activities to develop novel oral drugs to manage inflammation and pain due to OA is anticipated to hinder the market expansion of OA injectable drugs in the coming years. For instance, in February 2022, Medivir AB published the post-hoc analysis of a randomized phase 2a clinical trial of MIV-711 and its symptomatic and structural benefits for pain management of OA. MIV-711 is an orally administered drug targeting both bone resorption and cartilage degradation.

Osteoarthritis Injectables Market Report Highlights
  • Hyaluronic Acid (HA) injections segment dominated the market in 2023, owing to its high prescription rate in OA.
  • Knee osteoarthritis segment dominated the market in 2023. Knee OA is a prevalent condition particularly affecting older individuals, with the U.S. witnessing it as the second leading cause of incapacity among men aged 50 years and above.
  • Hospital pharmacies segment dominated the market in 2023. Hospital pharmacies play a pivotal role in osteoarthritis management, owing to factors such as higher number of treatments performed in the hospital setting.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Injection Type
1.2.2. End-use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Injection Type
2.2.2. End-use
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Global Osteoarthritis Injectables Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of osteoarthritis
3.2.1.2. Growing geriatric population susceptible to osteoarthritis
3.2.1.3. Increase in R&D activities for injectable drug development
3.2.2. Market restraint analysis
3.2.2.1. Adoption of other treatment options
3.2.2.2. High cost of treatment
3.3. Global Osteoarthritis Injectables Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.2.4. Pricing Analysis
3.3.3. Pricing Analysis
Chapter 4. Global Osteoarthritis Injectables Market: Injection Type Estimates & Trend Analysis
4.1. Injection Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Osteoarthritis Injectables Market by Injection Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Hyaluronic Acid Injections
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Corticosteroid Injections
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Platelet-rich Plasma (PRP) Injections
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Placental Tissue Matrix (PTM) Injections
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Acetylsalicylic Acid (ASA) Injections
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. Others
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Global Osteoarthritis Injectables Market: Anatomy Estimates & Trend Analysis
5.1. Anatomy Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Osteoarthritis Injectables Market by Anatomy Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Knee Osteoarthritis
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Hip Osteoarthritis
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Hand Osteoarthritis
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Others
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Global Osteoarthritis Injectables Market: End-use Estimates & Trend Analysis
6.1. End-use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Osteoarthritis Injectables Market by End-use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospital Pharmacies
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Retail Pharmacies
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Others
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Global Osteoarthritis Injectables Market: Regional Estimates & Trend Analysis by
7.1. Regional Market Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Mexico
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Anika Therapeutics, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Injection Type benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Bioventus.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Injection Type benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Ferring Pharmaceuticals Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Injection Type benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Sanofi S.A.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Injection Type benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Flexion Therapeutics, Inc.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Injection Type benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Zimmer Biomet
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Injection Type benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Arthrex, Inc.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Injection Type benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Royal Biologics
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Injection Type benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Teva Pharmaceutical Industries Ltd.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Injection Type benchmarking
8.3.12.4. Strategic initiatives
Chapter 9. Conclusion and Analyst Perspective

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings